PFDN4 and triple-negative breast carcinoma: In our study, we present evidence that PFDN4 overexpression is associated with a higher incidence of chemoresistance in triple-negative breast cancer than in non-triple-negative breast cancer, and is also a prognostic factor for poor prognosis in patients receiving chemotherapy.